Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Pharmather Hldgs Ltd (PHRRF)

Pharmather Hldgs Ltd (PHRRF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade PHRRF with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1463 +32.74%
on 09/03/24
0.2408 -19.35%
on 09/11/24
+0.0282 (+16.99%)
since 08/16/24
3-Month
0.1400 +38.71%
on 07/08/24
0.2408 -19.35%
on 09/11/24
+0.0376 (+24.01%)
since 06/18/24
52-Week
0.0831 +133.69%
on 09/22/23
0.3200 -39.31%
on 03/19/24
+0.1042 (+115.78%)
since 09/18/23

Most Recent Stories

More News
PharmaDrug's Sairiyo Therapuetics Provides Strategic Plans to Advance PD-001 (Patented Reformulated Cepharanthine) for Viral Infectious Diseases

Toronto, Ontario--(Newsfile Corp. - August 28, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development...

PHRRF : 0.1942 (+2.21%)
LMLLF : 0.0211 (+30.25%)
PHRM.CN : 0.2600 (+6.12%)
PHRX.CN : 0.0200 (unch)
PharmaTher Announces Notice of Allowance for U.S. Patent Covering Ketamine for the Potential Treatment of Parkinson’s Disease and Motor Disorders

TORONTO, July 13, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty...

PHRRF : 0.1942 (+2.21%)
PHRM.CN : 0.2600 (+6.12%)
PharmaTher Announces Positive Results from Study For Ketamine Microneedle Patch

Successfully delivered ketamine and KETABET™ (ketamine and betaine) via microneedle patch, unlocking the potential for desired dosage forms and...

PHRM.CN : 0.2600 (+6.12%)
PHRRF : 0.1942 (+2.21%)
PharmaTher To Develop and Commercialize Novel Wearable Ketamine Delivery Device in Collaboration with CCBIO

Wearable ketamine delivery device complements PharmaTher’s ketamine product portfolio, including injectable, intravenous, and microneedle patch PharmaTher...

PHRM.CN : 0.2600 (+6.12%)
PHRRF : 0.1942 (+2.21%)
PharmaTher Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Recent Business Highlights and Update

Nearly $12 million in cash and investment Fully funded for the Company’s development programs, including ketamine injection and infusion product,...

PHRM.CN : 0.2600 (+6.12%)
PHRRF : 0.1942 (+2.21%)
PharmaTher Signs Exclusive Worldwide License Agreement for Patented Formulation and Production Process of Ketamine and Ketamine Analogs

PharmaTher to file ANDA and 505(b)(2) regulatory submissions with the FDA for novel uses, delivery forms and formulations of ketamine for mental health,...

PHRRF : 0.1942 (+2.21%)
PHRM.CN : 0.2600 (+6.12%)
PharmaTher Announces Positive Topline Results from Clinical Study of Ketamine for Parkinson’s Disease

100% of patients treated with ketamine demonstrated reduction in dyskinesias as measured by the Unified Dyskinesia Rating Scale Ketamine was well...

PHRM.CN : 0.2600 (+6.12%)
PHRRF : 0.1942 (+2.21%)
PharmaTher Announces Grant of U.S. Patent on Ketamine Formulation

TORONTO, Feb. 16, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a leader in specialty...

PHRRF : 0.1942 (+2.21%)
PHRM.CN : 0.2600 (+6.12%)
PharmaTher Granted FDA Orphan Drug Designation for Ketamine to Treat Status Epilepticus

Third FDA orphan drug designation for ketamine granted to PharmaTher...

PHRRF : 0.1942 (+2.21%)
PHRM.CN : 0.2600 (+6.12%)
PharmaTher Announces FDA Approval of Investigational New Drug (IND) Application for Ketamine to Treat ALS

TORONTO, Jan. 12, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a company focused on the...

PHRRF : 0.1942 (+2.21%)
PHRM.CN : 0.2600 (+6.12%)

Key Turning Points

3rd Resistance Point 0.2200
2nd Resistance Point 0.2100
1st Resistance Point 0.2000
Last Price 0.1942
1st Support Level 0.1800
2nd Support Level 0.1700
3rd Support Level 0.1600

See More

52-Week High 0.3200
Fibonacci 61.8% 0.2295
Fibonacci 50% 0.2015
Last Price 0.1942
Fibonacci 38.2% 0.1736
52-Week Low 0.0831

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar